These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19108985)

  • 21. Lipid abnormalities during ART: it's the drug, not the class.
    Moyle GJ
    AIDS Read; 2004 Jan; 14(1):15-6, 20-2. PubMed ID: 14959700
    [No Abstract]   [Full Text] [Related]  

  • 22. High serum urate in HIV-infected persons: the choice of the antiretroviral drug matters.
    Walker UA; Hoffmann C; Enters M; Thoden J; Behrens G; Mitzel SL
    AIDS; 2006 Jul; 20(11):1556-8. PubMed ID: 16847413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Metabolic changes in PI-based HAART. Change to atazanavir: continued effectiveness with improved lipid profile].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():42-3. PubMed ID: 19024917
    [No Abstract]   [Full Text] [Related]  

  • 25. HIV infection and the pancreas: risk factors and potential management guidelines.
    Manfredi R; Calza L
    Int J STD AIDS; 2008 Feb; 19(2):99-105. PubMed ID: 18334062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HAART influences the lipids].
    Behrens G
    MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
    [No Abstract]   [Full Text] [Related]  

  • 27. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular risks of antiretroviral therapy.
    Stein JH
    N Engl J Med; 2007 Apr; 356(17):1773-5. PubMed ID: 17460232
    [No Abstract]   [Full Text] [Related]  

  • 30. Unexpected improvement of sexual dysfunction during atazanavir therapy.
    Colebunders R; Moerman F; Nöestlinger C
    AIDS; 2006 May; 20(8):1209-10. PubMed ID: 16691078
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased risk of renal stones in patients treated with atazanavir.
    Tattevin P; Revest M; Chapplain JM; Ratajczak-Enselme M; Arvieux C; Michelet C
    Clin Infect Dis; 2013 Apr; 56(8):1186. PubMed ID: 23300244
    [No Abstract]   [Full Text] [Related]  

  • 32. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
    Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
    Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 35. [Influence of anitiretroviral therapy on bone tissue metabolism in patients with HIV].
    Olczak A; Pawłowska M; Drózdz W
    Przegl Epidemiol; 2008; 62(1):155-62. PubMed ID: 18536239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
    AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs.
    Thoden J; Lebrecht D; Venhoff N; Neumann J; Müller K; Walker UA
    AIDS; 2008 May; 22(9):1093-4. PubMed ID: 18520357
    [No Abstract]   [Full Text] [Related]  

  • 38. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
    Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
    Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
    Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
    Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
    Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.